Does Weight Gain with Imovane Increase Drowsiness Risk?
Weight gain itself does not directly increase the risk of drowsiness from Imovane (zopiclone), but zopiclone independently causes residual daytime sedation and psychomotor impairment regardless of weight changes.
Understanding Zopiclone's Drowsiness Profile
Zopiclone carries inherent risks of next-day sedation that are dose-dependent and unrelated to weight changes:
- At the standard 7.5 mg dose, zopiclone produces minimal residual impairment, but volunteers report decreased alertness and some sleepiness on awakening 1.
- At 10 mg doses, significant psychomotor impairment persists up to 12 hours after administration 1.
- Zopiclone causes similar inhibition of psychomotor function the day after intake compared to nitrazepam, despite causing less subjective "hangover" 2.
Weight Gain and Hypnotics: No Direct Connection
The relationship between weight and drowsiness with zopiclone is not established:
- Benzodiazepines, non-benzodiazepine hypnotics (including zopiclone), and melatonergic agents are weight-neutral medications 3.
- No evidence links weight changes to altered drowsiness risk specifically with zopiclone use 3.
If weight gain is occurring during zopiclone treatment, consider alternative causes such as:
- Concurrent psychotropic medications (antipsychotics, certain antidepressants, mood stabilizers)
- Improved sleep leading to metabolic changes
- Lifestyle factors unrelated to the hypnotic
Clinical Safety Considerations for Drowsiness Risk
The primary drowsiness concerns with zopiclone relate to dose, age, and duration of use—not weight:
- In older adults with Alzheimer's disease, zopiclone 7.5 mg caused intense daytime sedation requiring discontinuation in some patients 4.
- Zopiclone is fairly tolerated overall with low rates of severe adverse events, though it produces non-severe impacts on psychomotor and cognitive performance 5.
- Restrict zopiclone use to ≤4 weeks and taper gradually (10-25% dose reduction weekly) to minimize dependence risk 6.
Practical Recommendations
To minimize drowsiness risk with zopiclone:
- Use the lowest effective dose (7.5 mg standard; consider lower doses in elderly or sensitive patients)
- Avoid doses exceeding 7.5 mg, as 10 mg produces measurable 12-hour psychomotor impairment 1
- Monitor for next-day impairment, cognitive/behavioral changes, and complex sleep behaviors 6
- Consider switching to eszopiclone if prolonged treatment is needed, as it has demonstrated efficacy up to 6 months with minimal cognitive/memory effects 6
If weight gain is problematic during treatment, investigate concurrent medications rather than attributing it to zopiclone itself 3.